Published in Clin Nucl Med on July 01, 2009
Prospective comparison of combined 18F-FDG and 18F-NaF PET/CT vs. 18F-FDG PET/CT imaging for detection of malignancy. Eur J Nucl Med Mol Imaging (2011) 1.63
Causes and imaging features of false positives and false negatives on F-PET/CT in oncologic imaging. Insights Imaging (2011) 1.23
Bone formation rather than inflammation reflects ankylosing spondylitis activity on PET-CT: a pilot study. Arthritis Res Ther (2012) 1.11
Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. Eur J Nucl Med Mol Imaging (2015) 0.98
PET and PET/CT imaging of skeletal metastases. Cancer Imaging (2010) 0.88
Bone scan or (18)f-fluorodeoxyglucose positron emission tomography/computed tomography; which modality better shows bone metastases of breast cancer? Breast Care (Basel) (2012) 0.78
Added value of using a cocktail of F-18 sodium fluoride and F-18 fluorodeoxyglucose in positron emission tomography/computed tomography for detecting bony metastasis: a case report. Medicine (Baltimore) (2015) 0.77
Skeletal metastases: what is the future role for nuclear medicine? Eur J Nucl Med Mol Imaging (2009) 0.75
Evaluation of Response to Therapy in a Patient with Lung Cancer: Correlation of Sclerotic Bone Lesions with F 18 FDG PET/CT and Bone Scintigraphy. Mol Imaging Radionucl Ther (2011) 0.75
VALIDATION OF THERAPEUTIC RESPONSE ASSESSMENT BY BONE SCINTIGRAPHY IN PATIENTS WITH BONE-ONLY METASTATIC BREAST CANCERS DURING ZOLEDRONIC ACID TREATMENT: COMPARISON WITH COMPUTED TOMOGRAPHY ASSESSMENT. Fukushima J Med Sci (2015) 0.75
Effect of Bone Reading CT software on radiologist performance in detecting bone metastases from breast cancer. Br J Radiol (2017) 0.75
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol (2013) 3.45
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol (2011) 2.50
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med (2013) 1.82
Radioembolization of the spleen: a revisited approach for the treatment of malignant lymphomatous splenomegaly. Cardiovasc Intervent Radiol (2012) 1.68
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol (2010) 1.61
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer (2011) 1.51
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study. BMC Cancer (2013) 1.43
The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. Radiother Oncol (2010) 1.40
Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. Nephrol Dial Transplant (2004) 1.38
Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging (2004) 1.30
Reducing loss of image quality because of the attenuation artifact in uncorrected PET whole-body images. J Nucl Med (2002) 1.17
Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiother Oncol (2004) 1.17
18FDG PET in oncology: the best and the worst (Review). Int J Oncol (2006) 1.09
Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy. Cancer Chemother Pharmacol (2008) 1.04
Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy. Clin Orthop Relat Res (2009) 1.04
A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int (2010) 1.03
Preservation of parotid function with uncomplicated conformal radiotherapy. Radiother Oncol (2002) 1.03
Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg (2004) 1.00
Novel treatment strategies for soft tissue sarcoma. Crit Rev Oncol Hematol (2006) 0.98
Molecular targeted therapies in breast cancer: where are we now? Int J Biochem Cell Biol (2007) 0.96
Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy. Eur J Nucl Med Mol Imaging (2012) 0.95
Is there a role for FGD-PET in radiotherapy planning in esophageal carcinoma? Radiother Oncol (2004) 0.94
Detection and characterization of tumor changes in 18F-FDG PET patient monitoring using parametric imaging. J Nucl Med (2011) 0.94
Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. Eur J Nucl Med Mol Imaging (2015) 0.93
European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer (2008) 0.91
A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res Treat (2014) 0.90
Clinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma. Oncol Rep (2006) 0.89
18F-fluoro-2-deoxy-D-glucose positron emission tomographic imaging: recent developments in head and neck cancer. Curr Opin Oncol (2005) 0.87
Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp. Anticancer Drugs (2006) 0.86
Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma. Arch Gynecol Obstet (2008) 0.84
Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer. Eur J Nucl Med Mol Imaging (2012) 0.84
Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres. Clin Nucl Med (2008) 0.83
Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. Eur J Cancer (2012) 0.83
Functional imaging of head and neck cancers. Curr Opin Oncol (2009) 0.81
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. J Clin Pharmacol (2011) 0.81
Treatment of patients with advanced soft tissue sarcoma: disappointment or challenge? Curr Opin Oncol (2007) 0.81
Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. Invest New Drugs (2008) 0.81
Lhermitte-Duclos disease: 11C-methionine positron emission tomography data in 4 patients. Surg Neurol (2006) 0.80
Advances in penile cancer management. Curr Opin Oncol (2010) 0.79
State of the art: radiolabeled microspheres treatment for liver malignancies. Expert Opin Pharmacother (2010) 0.78
Role of positron emission tomography in the management of head and neck cancer in the molecular therapy era. Curr Opin Oncol (2008) 0.78
New therapeutic developments in renal cell cancer. Crit Rev Oncol Hematol (2008) 0.76
A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies. Curr Med Res Opin (2007) 0.76
New PET imaging agents in the management of solid cancers. Curr Opin Oncol (2012) 0.76
Vertebral Hemangioma Mimicking Bone Metastasis in 68Ga-PSMA Ligand PET/CT. Clin Nucl Med (2017) 0.75
A case of acute lead poisoning in a 2-year-old child. Br J Clin Pharmacol (2006) 0.75
[Kidney cancer: from biology to clinical medicine]. Rev Med Suisse (2006) 0.75
Optimizing the use of PET with selective internal radiation therapy. Future Oncol (2014) 0.75
Nicotine does not compromise resting myocardial blood flow autoregulation in smokers at high cardiovascular risk. Nicotine Tob Res (2008) 0.75
Extra-skeletal Ewing's sarcoma in adults: presentation of two cases. Acta Orthop Belg (2010) 0.75
Dural metastases responsible for benign vertebral collapses. Eur J Nucl Med Mol Imaging (2007) 0.75
[Guidelines of clinical practice made by the European Lung Cancer Working Party: updates]. Rev Med Brux (2014) 0.75
A plea for the elective inclusion of the brain in routine whole-body FDG PET. Eur J Nucl Med Mol Imaging (2005) 0.75
Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial. Acta Gastroenterol Belg (2007) 0.75
Unusual diffuse liver (18)F-FDG uptake in melanoma patient treated by ipilimumab. Hell J Nucl Med (2017) 0.75
[Humanitarian ethics and the concept of justice]. Can J Public Health (2011) 0.75
Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. Clin Cancer Res (2002) 0.75